Ming‐Lung Yu

22.3k total citations · 1 hit paper
490 papers, 10.8k citations indexed

About

Ming‐Lung Yu is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Ming‐Lung Yu has authored 490 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 364 papers in Epidemiology, 352 papers in Hepatology and 41 papers in Surgery. Recurrent topics in Ming‐Lung Yu's work include Liver Disease Diagnosis and Treatment (307 papers), Hepatitis C virus research (303 papers) and Hepatitis B Virus Studies (233 papers). Ming‐Lung Yu is often cited by papers focused on Liver Disease Diagnosis and Treatment (307 papers), Hepatitis C virus research (303 papers) and Hepatitis B Virus Studies (233 papers). Ming‐Lung Yu collaborates with scholars based in Taiwan, United States and China. Ming‐Lung Yu's co-authors include Wan‐Long Chuang, Chia‐Yen Dai, Jee‐Fu Huang, Zu‐Yau Lin, Chung‐Feng Huang, Liang‐Yen Wang, Shinn‐Cherng Chen, Ming‐Lun Yeh, Ming‐Yen Hsieh and Ming‐Yuh Hsieh and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ming‐Lung Yu

471 papers receiving 10.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region

2023 79 citations Ming‐Lung Yu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ming‐Lung Yu Taiwan	53	7.7k	7.4k	1.1k	810	744	490	10.8k
Wan‐Long Chuang Taiwan	53	8.3k 1.1×	8.5k 1.1×	939 0.8×	563 0.7×	732 1.0×	513	11.1k
Keyur Patel United States	47	5.2k 0.7×	5.3k 0.7×	1.8k 1.6×	438 0.5×	566 0.8×	175	8.5k
San‐Lin You Taiwan	52	7.9k 1.0×	6.3k 0.8×	1.1k 1.0×	402 0.5×	1.0k 1.4×	181	11.4k
Graeme Alexander United Kingdom	49	7.2k 0.9×	7.2k 1.0×	1.3k 1.2×	481 0.6×	1.6k 2.1×	191	11.9k
Yoichi Hiasa Japan	43	4.2k 0.6×	3.9k 0.5×	765 0.7×	755 0.9×	1.2k 1.6×	406	7.2k
Ramsey Cheung United States	42	5.5k 0.7×	4.4k 0.6×	600 0.5×	1.1k 1.4×	678 0.9×	211	7.4k
Chia‐Yen Dai Taiwan	42	4.6k 0.6×	4.5k 0.6×	764 0.7×	450 0.6×	332 0.4×	354	6.5k
Calogero Cammà Italy	62	8.4k 1.1×	7.5k 1.0×	586 0.5×	1.1k 1.3×	2.3k 3.1×	271	12.0k
Robert J. de Knegt Netherlands	42	5.1k 0.7×	4.5k 0.6×	541 0.5×	607 0.7×	574 0.8×	235	7.2k
Morikazu Onji Japan	47	4.0k 0.5×	3.6k 0.5×	761 0.7×	593 0.7×	1.1k 1.5×	313	7.3k

Countries citing papers authored by Ming‐Lung Yu

Since Specialization

Citations

This map shows the geographic impact of Ming‐Lung Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming‐Lung Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming‐Lung Yu more than expected).

Fields of papers citing papers by Ming‐Lung Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming‐Lung Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming‐Lung Yu. The network helps show where Ming‐Lung Yu may publish in the future.

Co-authorship network of co-authors of Ming‐Lung Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Ming‐Lung Yu. A scholar is included among the top collaborators of Ming‐Lung Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming‐Lung Yu. Ming‐Lung Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alqahtani, Saleh A., et al.. (2025). Energy metabolism: An emerging therapeutic frontier in liver fibrosis. Annals of Hepatology. 30(1). 101896–101896. 1 indexed citations

Huang, Chung‐Feng, Chih‐Wen Wang, Tyng‐Yuan Jang, et al.. (2024). Surveillance Imaging and GAAD/GALAD Scores for Detection of Hepatocellular Carcinoma in Patients with Chronic Hepatitis. Journal of Clinical and Translational Hepatology. 0(0). 0–0. 4 indexed citations

Huang, Chung‐Feng, Po‐Cheng Liang, Chih‐Wen Wang, et al.. (2024). Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis. The Kaohsiung Journal of Medical Sciences. 40(4). 374–383. 3 indexed citations

Huang, Chung‐Feng, et al.. (2024). Chronic Hepatitis C Related Steatotic Liver Disease Is More Than “Miscellaneous Steatotic Liver Disease”. Clinical Gastroenterology and Hepatology. 22(10). 2137–2139.e2. 5 indexed citations

Alqahtani, Saleh A., Wah‐Kheong Chan, & Ming‐Lung Yu. (2023). Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma. Clinics in Liver Disease. 27(2). 211–223. 14 indexed citations

Cheng, Pin‐Nan, Hsing‐Tao Kuo, Pei‐Lun Lee, et al.. (2023). Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B. Alimentary Pharmacology & Therapeutics. 59(2). 230–238. 8 indexed citations

Jang, Tyng‐Yuan, Po‐Cheng Liang, Yu‐Ju Wei, et al.. (2023). Air pollution associate with advanced hepatic fibrosis among patients with chronic liver disease. The Kaohsiung Journal of Medical Sciences. 40(3). 304–314. 10 indexed citations

Tsai, Yi‐Shan, Ching‐I Huang, Pei‐Chien Tsai, et al.. (2022). Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients. Cancers. 14(8). 2023–2023. 6 indexed citations

Hong, Chun‐Ming, Chun‐Jen Liu, Shiou‐Hwei Yeh, et al.. (2021). Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan. Viruses. 13(11). 2294–2294. 1 indexed citations

10.

Jang, Tyng‐Yuan, Chung‐Feng Huang, Chia‐Yen Dai, et al.. (2021). The Prevalence and Serological Association of Hepatitis D Virus Genotypes in Taiwan. Pathogens. 10(10). 1227–1227. 1 indexed citations

11.

Li, Chia‐Yang, Wei‐Chung Cheng, Chung‐Feng Huang, et al.. (2021). The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interluekin-8 Expression. Biomedicines. 9(10). 1446–1446. 4 indexed citations

12.

Liang, Po‐Cheng, Chung‐Feng Huang, Ming‐Lun Yeh, et al.. (2020). Real‐world effectiveness of direct‐acting antiviral agents for chronic hepatitis C patients with genotype‐2 infection after completed treatment. The Kaohsiung Journal of Medical Sciences. 37(4). 334–345. 7 indexed citations

13.

Wang, Shu‐Chi, Chia‐Yang Li, Wen‐Tsan Chang, et al.. (2020). Exosome‐derived differentiation antagonizing non‐protein coding RNA with risk of hepatitis C virus‐related hepatocellular carcinoma recurrence. Liver International. 41(5). 956–968. 22 indexed citations

14.

Huang, Ching‐I, Ming‐Lun Yeh, Chung‐Feng Huang, et al.. (2018). Association between cryoglobulinemia and liver fibrosis in chronic hepatitis C patients. Journal of Gastroenterology and Hepatology. 33(11). 1897–1903. 8 indexed citations

15.

Yu, Ming‐Lung, Chung‐Feng Huang, Ming‐Lun Yeh, et al.. (2016). Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment. Clinical Cancer Research. 23(7). 1690–1697. 26 indexed citations

16.

Yin, Jianhua, Rui Pu, Haiguang Xin, et al.. (2015). Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study. Cancer Prevention Research. 8(10). 978–988. 21 indexed citations

17.

Tai, Chi‐Ming, Chih‐Kun Huang, Hung‐Pin Tu, et al.. (2014). PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease. Surgery for Obesity and Related Diseases. 11(4). 888–894. 16 indexed citations

18.

Dai, Chia‐Yen, Ming‐Lun Yeh, Chung‐Feng Huang, et al.. (2013). Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. Journal of Gastroenterology and Hepatology. 30(5). 879–884. 54 indexed citations

19.

Hsieh, Meng‐Hsuan, Li‐Po Lee, Ming‐Yen Hsieh, et al.. (2007). Hepatic Steatosis and Fibrosis in Chronic Hepatitis C in Taiwan. Japanese Journal of Infectious Diseases. 60(6). 377–381. 22 indexed citations

20.

Yang, Jeng‐Fu, Chia‐Yen Dai, Wan‐Long Chuang, et al.. (2006). Prevalence and Clinical Significance of HGV/GBV-C Infection in Patients with Chronic Hepatitis B or C. Japanese Journal of Infectious Diseases. 59(1). 25–30. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact